Summary

The global swine vaccines market is expected to grow at a significant rate of around 5% during the forecast period. Swine vaccines are vaccines that are specifically designed to prevent or control diseases in pigs. These vaccines contain either live, attenuated, or inactivated forms of pathogens that can cause diseases in pigs, such as influenza, porcine reproductive and respiratory syndrome (PRRS), and porcine circovirus type 2 (PCV2). The swine vaccine market is expected to grow in the coming years due to the increasing demand for pork, the growing prevalence of swine diseases, and the development of advanced vaccine technologies.

The increasing swine disease outbreaks and zoonotic disease, together with the widespread use of antibiotic-free disease prevention techniques, are some of the major reasons driving the market's expansion. Porcine reproductive and respiratory syndrome (PRRS) and swine influenza continue to be extremely common among swine herds in Asia, Europe, and America, causing significant economic damage. Hence, swine producers are widely employing biosecurity procedures and vaccination techniques to reduce the impact. For instance, the OIE (Office International des Epizooties), reports that between 2016 and 2020 there were 9,928 outbreaks of African swine fever in Asian swine herds, followed by 4,721 occurrences in Europe.

Merck & Co., Inc.; Ceva; Zoetis; Boehringer Ingelheim International GmbH; Elanco; Indian Immunologicals Ltd.; Biogénesis Bagó; Phibro Animal Health Corporation; KM Biologics; and HIPRA, S.A. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report
“Amongst product type, inactivated vaccines category to witness robust CAGR during the forecast period.”
Based on product type, the market is segmented into attenuated live vaccines, inactivated vaccines, subunit vaccines, DNA vaccines, and recombinant vaccines. The inactivated vaccines category to witness higher CAGR during the forecast period. This is mainly due to the use of inactivated vaccines in swine production is driven by the need to protect the health of the animals, improve productivity, comply with regulatory requirements, and meet consumer demands. As technology continues to advance, we can expect to see continued growth in the use of inactivated vaccines in swine production.

“Amongst type, the swine influenza held a significant share in the market in 2021.”
On the basis of type, the market is categorized into swine influenza, classical swine fever, porcine parvovirus, porcine circovirus type 2, and m.hyo. Among these, swine influenza held a significant share of the market in 2021. This is mainly due to reducing the risk of transmission of the virus to humans, complying with regulatory requirements, meeting consumer demands, and taking advantage of advancements in vaccine technology. As the risks associated with swine influenza continue to be recognized, can expect to see continued growth in the use of swine influenza vaccines in swine vaccine production.

“North America to hold a significant share in the market”
For a better understanding of the market adoption of the swine vaccines industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to several factors, including the rising demand for animal protein, the increasing prevalence of swine diseases, and the need to improve animal health and productivity, the demand for swine vaccines is expected to continue to grow. Advances in vaccine technology are also expected to further drive growth in the market, making it an exciting time for the swine vaccines industry in North America. For instance, in February 2021, Algenex SL and Virbac proclaimed that they have entered an international licensing agreement for the development and commercialization of a CrisBio-based vaccine in a key swine indication.

Reasons to buy this report:
• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
• The report presents a quick review of overall industry performance at one glance.
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
• The study comprehensively covers the market across different segments.
• Deep dive regional level analysis of the industry.

Customization Options:
The global swine vaccines market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

ページTOPに戻る

Table of Contents